ReSPECT-GBM Phase 1 recurrent glioblastoma trial demonstrates safety and overall survival correlation with absorbed radiation dose ReSPECT-LM Phase 1/Part A...
June 29, 2023News release BioPorto Announces Submission of Response to FDA Additional Information Letter COPENHAGEN, DENMARK and BOSTON, MA, June...
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- June 28, 2023 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB)...
LifeArc strengthens Board of Trustees with new appointments 27 June 2023: LifeArc, the self-funded medical research organisation, announces today that...
Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE...
Signs Diagnostics Services Agreement with Neurovative DiagnosticsDENVER, June 27, 2023 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “Company” or “Assure”)...
Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly-owned by the...
Patent EP 3 332 028 B1 granted by the European Patent Office covers the identification and use of genomic variants...
Following final assembly and successful testing, a batch of ten Unyvero A30 instrument systems has been receivedLatest C-Series Unyvero A30...
HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...
MUNICH, Germany, June 21, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a global clinical-stage biopharmaceutical company,...
June 21, 2023Announcement no. 11 BioPorto A/S announces results of rights issue COPENHAGEN, Denmark and BOSTON, MA, USA, June 21,...
Emergex and Brazil’s IBMP to co-fund Phase II and Phase III studies of Emergex’s Dengue Fever and Betacoronavirus T cell-priming...
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patientsMUNICH, Germany, June 20, 2023 (GLOBE NEWSWIRE)...
Per Protocol Participants saw an 85% Reduction in the Loss of Vertebral Bone Density in One YearCHICAGO, June 16, 2023...
Venlo, the Netherlands, June 16, 2023 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today a...
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted...
The study represents a significant breakthrough in understanding the potential for reversing and measuring epigenetic changes associated with coronary heart...
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded...
New panel will enable rapid, precise genetic profiling of patients with deadly diseaseNEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE)...